Hanmi Pharmaceutical's First Outside CEO Hwang Sangyeon: "30 Years with Hanmi... Will Dispel Concerns"
Concerns Over Appointment of First External CEO in 53 Years
"I Have a 30-Year Relationship With Hanmi... Maximizing R&D Capabilities"
Hwang Sangyeon, the new CEO of Hanmi Pharmaceutical and the first outsider to be appointed as CEO since the company's founding, has expressed his determination not to compromise the company’s research and development (R&D) competitiveness, which has established its reputation as a "powerhouse of new drug development."
Speaking with reporters immediately after the annual shareholders’ meeting held on the 31st at Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul, CEO Hwang stated, "While people inside and outside the company say that I am the first external CEO in Hanmi Pharmaceutical's history, personally, my connection with Hanmi spans more than 30 years." He added, "I will work diligently with the goal of taking Hanmi Pharmaceutical, already the undisputed No. 1 pharmaceutical company in Korea, to the next level," emphasizing, "I will deliver management results that meet expectations and dispel concerns."
Hwang Sangyeon, the new CEO of Hanmi Pharmaceutical, is answering questions from the press immediately after the shareholders' meeting held on the 31st at Hanmi Pharmaceutical headquarters in Songpa-gu, Seoul. Photo by Park Jeongyeon
View original imageCEO Hwang is a financial and investment expert who has served as head of a securities firm research center and as an investment manager at a global asset management company. This is the first time in 53 years since its founding that Hanmi Pharmaceutical has appointed an external figure as CEO.
Addressing recent concerns about a possible decline in quality due to cost-cutting measures, Hwang drew a clear line by stressing the fundamental principles of the pharmaceutical industry. He explained, "Pharmaceutical raw materials must meet a certain standard, and only qualified ingredients that have passed the Drug Master File (DMF) registration system can be used for production. This is a core principle." He continued, "Within the scope of important regulatory requirements being met, we will pursue economic rationality and act in the best interests of our customers."
On the issue of corporate governance and stabilizing the professional management system, he emphasized adherence to the law and common sense. He said, "If we remain faithful to legal and commonsense principles and focus on creating value for customers, employees, and shareholders, all concerns will be addressed. The intent of the revised Commercial Act is to maximize the interests of all shareholders rather than favoring any particular one, and I will manage the company based on that." He also added, "I will always keep in mind the late chairman’s management principles of respect for humanity and value creation."
Regarding the relationship with holding company Hanmi Science, Hwang mentioned balancing independent management with cooperation. He said, "I have had a close professional relationship with Vice Chairman Kim Jaegyo for many years, learning from him as a mentor. The holding company coordinates the entire group, while subsidiaries maximize business value according to that direction. I will consult frequently, but will maintain an independent management perspective."
On his concrete management plans, CEO Hwang stated, "I have several ambitious ideas aimed at maximizing Hanmi Pharmaceutical’s accumulated R&D capabilities and production standards. I will deliver results step by step to meet expectations."
At the shareholders’ meeting, the appointment of Kim Nayoung, Head of New Product Development at Hanmi Pharmaceutical (inside director), Han Taejun, President of Ghent University Global Campus (outside director), and former National Assemblyman Chae Ibae (outside director) was approved, as well as the reappointment of Kim Taeyoon, professor at Hanyang University, as outside director. Hanmi Science also held its regular shareholders’ meeting at Hanmi Group headquarters and passed agenda items including the appointment of Namgyu Kim, CEO of La Defense Partners—one of the four-party alliance members (Chairman Shin Dongguk, Chairwoman Song Youngsook, Vice Chairman Lim Joohyun, and La Defense)—as a new non-executive director.
As a result, the management dispute at Hanmi Pharmaceutical, which had surfaced last month, has now been settled. Last month, former CEO Park Jaehyun raised issues, claiming that controlling shareholder Shin Dongguk, Chairman of Hyanyang Precision, was unjustly interfering in management. Early this month, Song Youngsook, Chairwoman of Hanmi Pharmaceutical Group, expressed support for the professional management system, stating, "The major shareholder should provide sound direction and support, rather than directly intervening in management."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Industry insiders had voiced concerns that the four-party alliance, which had been maintained after the 2024 management rights dispute, might be destabilized. However, with the failure of former CEO Park’s bid for reappointment and the selection of new CEO Hwang, the controversy over major shareholder ‘management interference’ appears to have been resolved for now.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.